How NMPA Class III Medical Device Approval Works in China

NMPA Class III is the highest-risk medical device category in China — the same regulatory tier that surgical robots, implantable orthopedic systems, and active diagnostic catheters fall into. Understanding how Class III approval works is the first step in evaluating any China-based medical robotics company, because the registration certificate determines what can actually be sold to a hospital.

What “Class III” Means

China’s medical device classification follows three risk-based tiers, defined in the Regulations on Supervision and Administration of Medical Devices:

• Class I — low risk, filed at the municipal level (record-keeping only)
• Class II — medium risk, registered at the provincial NMPA branch
• Class III — high risk, registered at the central NMPA in Beijing

Surgical robots, vascular interventional systems, neurosurgical positioning robots, and capsule endoscopes are all Class III. So is anything that supports or sustains life, anything that goes inside the body, and anything where failure could cause serious injury.

The classification is determined by the Medical Device Classification Catalog, periodically revised by the NMPA. Surgical robots fall under category 01 (Active Surgical Instruments) or category 03 (Auxiliary Surgical Equipment) depending on configuration.

The Registration Pathway

A typical Class III registration goes through five phases:

1. Pre-Submission Strategy

Before any clinical work begins, the manufacturer determines:

• The exact intended use statement (this drives every later decision)
• Whether the device qualifies for the Innovation Green Channel (see NMPA Innovative Medical Device Green Channel Explained)
• Predicate devices and substantial equivalence arguments where applicable
• The clinical evaluation strategy — China usually requires Chinese trial data even when foreign data exists

2. Quality System Audit

The manufacturer must operate under China’s Good Manufacturing Practice for Medical Devices (GMP). For Class III devices, the NMPA conducts an on-site audit before registration is granted. International manufacturers without a Chinese factory typically partner with a domestic OEM or set up a wholly-owned manufacturing subsidiary — the Intuitive-Fosun joint venture is a well-known example of this structure.

3. Clinical Trial

Class III medical robotics typically require a multi-center prospective clinical trial in China, conducted under NMPA Good Clinical Practice. Sample sizes vary by indication but commonly fall between 100 and 300 patients per indication. The trial protocol must be filed and approved before enrollment begins.

For a robotic system with multiple intended uses (e.g., a laparoscopic surgical robot covering urology, gynecology, and general surgery), each indication may need its own trial cohort or a stratified study design. This is one reason why companies often pursue indication expansion through subsequent supplemental approvals rather than packing everything into the initial registration.

4. Technical Review

The Center for Medical Device Evaluation (CMDE) conducts the substantive technical review. The standard review clock for Class III devices is approximately 60 working days for the first review round, with multiple rounds typical. Total elapsed time from submission to approval commonly runs 18–24 months for non-Innovation-Channel devices.

CMDE evaluates:

• Performance specifications and verification testing
• Risk management documentation per ISO 14971
• Sterilization and biocompatibility (for sterile or implant-contact devices)
• Software lifecycle documentation per IEC 62304
• Cybersecurity (for connected devices)
• Clinical evidence including the Chinese trial

5. Registration Certificate

When approved, the manufacturer receives a Medical Device Registration Certificate (国械注准 for domestic, 国械注进 for imported). The certificate format is:

国械注准YYYYNNNNNNN

Where YYYY is the year and NNNNNNN is a sequential number plus a category prefix. For example, the Toumai SP single-port surgical robot carries registration number 20253010347 — the “302” prefix encodes Active Surgical Instruments at Class III, and “10347” is the year-indexed sequence.

Registration certificates are valid for five years. Renewal requires a fresh quality system audit and updated technical documentation, but generally not a new clinical trial unless the device or its claims have materially changed.

What’s Different About Robotic Surgery Class III Reviews

NMPA reviews of surgical robots involve specialized considerations beyond conventional medical devices:

Software validation gets more scrutiny. Robotic surgical systems have substantial software content — control algorithms, safety interlocks, real-time motion processing. CMDE requires detailed software lifecycle documentation, including hazard analysis for each safety-relevant software unit.

Clinical operator training is part of the registration. Unlike a passive implant where operator skill is assumed, robotic systems require documented training programs, and the registration may stipulate that only trained operators can use the system.

The training pathway is itself reviewable. For complex platforms, CMDE may evaluate the proficiency assessment criteria for credentialing surgeons.

Cybersecurity for telesurgical capability. Robots with 5G or remote-operation capability — like Toumai Tele-Robotic System or KangDuo SR2000 — face additional review of communication security, latency monitoring, and emergency disengagement protocols.

Comparison Snapshot

How NMPA Class III compares to similar regulatory tiers globally:

Note that the FDA system also includes 510(k) clearance, which is a separate “substantial equivalence” pathway for devices not requiring PMA — see FDA 510(k) vs PMA vs De Novo Pathways Compared.

What This Means for Buyers and Researchers

When evaluating a Chinese surgical robot manufacturer, the registration certificate is the single most important regulatory document:

• No Class III certificate, no clinical sale. A device with only Class II clearance or no NMPA registration cannot be used for Class III intended purposes regardless of company claims.
• The intended use statement is binding. A robot approved for laparoscopic urology cannot be commercially marketed for cardiac surgery, even if technically capable.
• Indication expansion happens through supplemental registrations. When a company adds new procedures to an existing system, each addition is an NMPA filing.
• Imported vs domestic registration matters. A China-domestic registration (国械注准) means manufacturing happens in China and pricing/access reflects that; imported registrations (国械注进) follow different commercial dynamics.

For a current view of the Chinese surgical robotics field as of late 2025, see our 2025 Year in Review.

Frequently Asked Questions

How long does NMPA Class III approval typically take?

For non-expedited reviews, the typical elapsed time from clinical trial completion to registration certificate is 18–24 months. The Innovation Green Channel can compress this for qualifying devices.

Does foreign clinical data count for NMPA?

Foreign data can support a registration, but for Class III medical robots the NMPA generally still requires a Chinese clinical trial with Chinese patients and Chinese investigators. The foreign data shortens design discussions but rarely eliminates the trial requirement.

What happens if a manufacturer modifies an approved Class III device?

Material changes — to indication, design, or manufacturing process — require a supplemental registration. Minor changes are filed via change notification. The boundary between “supplemental” and “notification” is detailed in CMDE guidance.

Can a foreign company get Class III approval without a Chinese subsidiary?

Yes, through a Designated China Agent. The agent holds the registration and conducts post-market surveillance on behalf of the foreign manufacturer. However, manufacturing must still meet NMPA GMP, audited on-site.

Is the NMPA Class III review process getting faster?

Yes. The 2024 reforms detailed in NMPA Announcement No. 63 introduced ten measures to optimize whole-life-cycle regulation, with surgical and rehabilitation robots named as priority categories. Innovation Green Channel approvals have accelerated meaningfully — see our 2025 Year in Review for context on the structural shift.